Interpace Diagnostics Group, Inc. announced that it has finalized the validation of its third specimen type for its molecular thyroid tests ThyGeNEX™ and ThyraMIR®. Interpace has expanded its services again to now also process specimens prepared in formalin fixed, paraffin-embedded (FFPE) samples. Prior to this validation, ThyGeNEXT and ThyraMIR the company is the only marketed molecular products validated with both RNARetain® and cytology slides. The company initiated a partnering arrangement with the Dianon Systems Inc. division of LabCorp and certain regional labs to provide customers with a one-stop service for molecular testing for indeterminate thyroid nodules. Interpace’s validation of cytology slides led to further expansion of its thyroid business in 2018 with former Rosetta Genomics customers when Rosetta filed for Chapter 7 bankruptcy. Interpace now offers the most expansive set of choices with the FFPE sample expansion of specimen options, enabling it to be flexible and responsive to all of its customers’ needs. This also provides an opportunity for further growth as those physicians, who use alternate providers, find this level of customization best suited to the manner in which they manage these specimens and patients in their practices.